Press Releases

Invitation to Presentation of Promore Pharma’s Year-end report for 2018

Subscription price for Promore Pharma’s warrants TO1 determined

PharmaResearch Products Ltd use call option in Promore Pharma

Nomination Committee Appointed for the Annual General Meeting 2019 in Promore Pharma

Promore Pharma has conducted Investigator Meeting for HEAL LL-37 in Poland

Promore Pharma Plans to Expand Indications of Therapeutic Peptide PXL01 in the Field of Dermal Scarring

Invitation to Presentation of Promore Pharma’s Interim report for the second quarter 2018

Invitation to Presentation of Promore Pharma’s Interim report for the first quarter 2018

Västra Hamnen Corporate Finance Initiates Coverage on Promore Pharma

Two new smart-phone based imaging products have been adopted by Promore Pharma AB

Promore Pharma is granted a patent for PXL01 in the US

Promore Pharma Signs Agreement with CRO PCG Clinical Services

Promore Pharma Completes Extensive European Collaboration Regarding DPK-060

Promore Pharma Signs Manufacturing Agreement with APL

Promore Pharma presents at the symposium for hard-to-heal wounds in connection with Nordic Life Science Days

Interim report January – March 2017

Promore Pharma AB files phase III clinical trial application in India

Promore Pharma AB elects Marianne Dicander Alexandersson as New Board Member and outlines plans for IPO

Promore Pharma and Cellastra Inc. Announce Phase III Clinical Collaboration to Develop Therapeutic Peptide PXL01 for the US Market

Promore Pharma is Seeking an Office Manager in Stockholm

New Chief Financial Officer in Promore Pharma

Promore Pharma Announces a Strategic Collaboration with Technomark Life Sciences

Pergamum AB and Lipopeptide AB Change Name to Promore Pharma

Promore Pharma Obtains Positive Feedback in Dialogue with The Medical Products Agency of Sweden

Lipopeptide AB Announces a Strategic Collaboration with Pharmaresearch Products LTD

Pergamum AB Announces Ownership Restructuring

Pergamum Announces Final Data from Phase I/II Study in Patients with Chronic Leg Ulcers

Pergamum Reports Positive Follow-Up Data from a Phase II Clinical Trial of PXL01 for Prevention of Post-Surgical Adhesions

Pergamum Announces a Strategic Collaboration with Cadila Pharmaceuticals Ltd.